Navigation Links
Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
Date:8/25/2013

ys of completion of the last therapy.  Approval is based on response rate.  Currently, no data are available for Kyprolis that demonstrate an improvement in progression-free survival or overall survival.

Important Safety Information Regarding Kyprolis® (carfilzomib) for Injection

On July 20, 2012, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Kyprolis® (carfilzomib) for Injection for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent (IMiD), and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval was based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.

Safety data have been evaluated in 526 patients with relapsed and/or refractory multiple myeloma who received single-agent Kyprolis. There were 37 deaths in the phase 2 studies, or 7% of patients. The most common causes of death, other than disease progression, were cardiac (5 patients), end-organ failure (4 patients), and infection (4 patients). Important warnings and precautions include cardiac arrest, congestive heart failure, myocardial ischemia; pulmonary hypertension, pulmonary complications, infusion reactions, tumor lysis syndrome, thrombocytopenia, hepatic toxicity and embryo-fetal toxicity.

Death due to cardiac arrest has occurred within a day of Kyprolis administration. Patients with New York Heart Association Class III and IV heart failure, myocardial infarction in the preceding 6 months, and conduction abnormalities uncontrolled by medications were not eligible for the clinical trials. These patients may be at greater risk for cardiac complications.

Pulmonary arterial hypertension (PAH) was reported in 2% of patients treated with Kyprolis and was Grade 3 or greater in less than 1% of patients. Dyspnea was reported in 35% o
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... -- Inmark,s acquisition of Saf-T-Pak last week positioned Inmark ... Division 6.2.  For over 25 years, Saf-T-Pak has ... on IATA, ICAO, US DOT, Transport Canada, RID/ADR ... were particularly interested in Saf-T-Pak,s proprietary Learning Management ... programs," said David Oyler , Inmark President ...
(Date:4/21/2015)... April 21, 2015 Global cap ... World demand for caps and closures will exceed $55 billion ... exceed two trillion annually. Beverages will continue to account for ... and a number of smaller markets are expected to register ... Although the most developed markets -- the US, ...
(Date:4/21/2015)... 2015 The global dermatology diagnostic devices market ... from 2014 to 2019. North America ... shares in the global dermatology diagnostic devices market. The ... mainly attributed to a wide range of factors, such ... dermatologists, and technological advancements made in the field of ...
Breaking Medicine Technology:Inmark's Acquisition Of Saf-T-Pak Results In Expansion Of Its Dangerous Goods Training Portfolio 2World Caps & Closures Market 2World Caps & Closures Market 3Dermatology Diagnostic Devices Market by Product, by End-User - Global Forecast to 2019 2Dermatology Diagnostic Devices Market by Product, by End-User - Global Forecast to 2019 3
... and NEW YORK, July 14, 2011 ... company leveraging its proprietary drug-delivery platforms to develop treatments ... announced that its lead product for oral mucositis, ... benefit network.  Reimbursement coverage for MuGard is now available ...
... BLUE BELL, Pa., July 14, 2011 Inovio Pharmaceuticals, ... in the development of therapeutic and preventive vaccines against ... cell and antibody responses were generated in its Phase ... for the prevention of avian H5N1 influenza delivered using ...
Cached Medicine Technology:Access Pharmaceuticals MuGard Added to CVS Caremark's Pharmacy Benefit Network 2Access Pharmaceuticals MuGard Added to CVS Caremark's Pharmacy Benefit Network 3Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 2Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 3Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 4Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 5Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 6Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 7Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 8Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 9
(Date:4/21/2015)... “ ZeroWire ” was featured on NewsWatch as ... look at the latest and coolest technology products and ... for NewsWatch and a technology expert, conducted the review ... system and lifestyle management hub. , According to the ... burglaries in 2010. It goes without saying that home ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 21, 2015 ... Review, H1 2015” provides comparative analysis on ... strengthens R&D pipelines by identifying new targets ... products. Complete report with TOC is available ... report also reviews key players involved in ...
(Date:4/21/2015)... NJ (PRWEB) April 21, 2015 ... across platforms and devices, today announced a new enhancement ... of the new Microsoft Office 365 Management Activity API. ... customers to fully audit and take action on all ... , “The new Office 365 Management Activity API provides ...
(Date:4/21/2015)... York, NY (PRWEB) April 21, 2015 ... of advanced delivery technologies and development solutions for ... the launch of ADVASEPT™ Lock, a stopper-less, glass- ... delivery of injectable medications. Easily opened, ADVASEPT Lock ... convenient and functional container closure with the security ...
(Date:4/21/2015)... 2015 The report “Dermatitis ... analysis on the therapeutic development for Dermatitis. ... identifying new targets and MOAs to produce ... TOC is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html ... players involved in the therapeutic development for ...
Breaking Medicine News(10 mins):Health News:A Leader in Home Security was Featured on NewsWatch Television 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 2Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 3Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4
... Smoking has been linked to a number of ... disorders, among others. Early smoking is shown to ... disorders (e.g., panic disorder, generalized anxiety disorder), and ... anxiety) increases the risk for later development of ...
... now become common place owing to the wide scale ... over again, scientists have been working on ways to ... results of a recent research have recently confirmed that ... diseases. ,The leeches have added to the ...
... A new study says that botulinum toxin can be useful ... trigeminal neuralgia. Botulinum or botox as it is popularly known ... and eye spasms. ,Researchers in Brazil and the United ... have detailed their findings in a study published in the ...
... Kollywood stars like Kamal Hassan, Chiranjeevi, Nagarjuna, Venkatesh, Vikram, ... to spread the awareness on AIDS. ,The show ... the Melinda and Bill Gates Foundation was an evening of ... anything in partnership with others. I am very proud of ...
... is likely to invoke the compulsory licensing (CL) provision ... //firms to produce and stockpile Swiss drug maker Roche’s ... against the most dreaded avian flu virus. , ... receipt of an application from the industry. Furthermore, the ...
... Abdominal wall hernias are one of the most common ... repairs// performed annually. Although ventral hernia repair (VHR) is ... problem. Wound infection has been identified as a consistent ... recent study, which appears in the November issue of ...
Cached Medicine News:Health News:Smokers Are Prone To Number Of Psychiatric Disorders 2Health News:Leeches Provide Clues Regarding The Prevention Of Heart Disease 2Health News:Predictors Of Wound Infection In Ventral Hernia Repair 2
Inquire...
The autoclavable, aluminum needle box is designed to store loaded needles and help protect personnel from exposure. Each shield consists of an aluminum box with faceplate to match the grid pattern th...
... Brachytherapy loaders allow for efficient, easy ... Connectors to your customized plans at ... Bard loaders is the flexibility to ... in the QuickLoad™ Loader allows for ...
... designed to help you achieve one important ... procedure. All needles are engineered for exceptional ... for smooth entry and exit. A broad ... an ideal match with procedural needs and ...
Medicine Products: